Bartomeu Massutí

1999–2025 年に発表

別表記
Bartomeu Massuti
98
論文数
19,502
被引用数
57
h 指数
88
i10 指数

被引用数

Bartomeu Massutí の年別被引用数1971 年: 被引用 4 件1993 年: 被引用 2 件1999 年: 被引用 2 件2000 年: 被引用 12 件2001 年: 被引用 9 件2002 年: 被引用 19 件2003 年: 被引用 17 件2004 年: 被引用 17 件2005 年: 被引用 15 件2006 年: 被引用 39 件2007 年: 被引用 53 件2008 年: 被引用 58 件2009 年: 被引用 58 件2010 年: 被引用 92 件2011 年: 被引用 133 件2012 年: 被引用 125 件2013 年: 被引用 213 件2014 年: 被引用 172 件2015 年: 被引用 215 件2016 年: 被引用 205 件2017 年: 被引用 190 件2018 年: 被引用 193 件2019 年: 被引用 549 件2020 年: 被引用 540 件2021 年: 被引用 617 件2022 年: 被引用 506 件2023 年: 被引用 463 件2024 年: 被引用 711 件2025 年: 被引用 434 件2026 年: 被引用 9 件1972〜1992 年は被引用が無いため表示していません1994〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,795 件、この内訳の 21.6%中国: 引用元論文 1,231 件、この内訳の 14.8%イタリア: 引用元論文 503 件、この内訳の 6%スペイン: 引用元論文 477 件、この内訳の 5.7%イギリス: 引用元論文 408 件、この内訳の 4.9%日本: 引用元論文 389 件、この内訳の 4.7%フランス: 引用元論文 360 件、この内訳の 4.3%ドイツ: 引用元論文 323 件、この内訳の 3.9%韓国: 引用元論文 240 件、この内訳の 2.9%オランダ: 引用元論文 236 件、この内訳の 2.8%カナダ: 引用元論文 225 件、この内訳の 2.7%スイス: 引用元論文 195 件、この内訳の 2.3%
0%21.6%その他 23.4%

分野

  • Medicine81.3%
  • Biochemistry, Genetics and Molecular Biology13.6%
  • Immunology and Microbiology2.5%
  • Engineering0.6%
  • Computer Science0.3%
  • Chemistry0.3%
  • その他1.4%

トピック

  • Lung Cancer Treatments and Mutations17.7%
  • Cancer Immunotherapy and Biomarkers8.1%
  • Lung Cancer Diagnosis and Treatment7.8%
  • Lung Cancer Research Studies7.6%
  • Cancer Genomics and Diagnostics5%
  • Colorectal Cancer Treatments and Studies4%
  • その他49.8%

共著者

全論文

検索で開く
  1. Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 450

  2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares - The Lancet Oncology 2012 被引用: 5,530

  3. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 被引用: 424

  4. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 828

  5. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 335

  6. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 被引用: 2,377

  7. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K. Sabari, Angel Qin, Dariusz M. Kowalski, Mehmet Alı Nahıt Şendur, John Xie, Debopriya Ghosh, Ali Alhadab, Nahor Haddish‐Berhane, Pamela L. Clemens, Patricia Lorenzini, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro, for the PALOMA-3 Investigators, Hiroaki Akamatsu, Mariam P. Alexander, Annalen Bleckmann, Federico Cappuzzo, Ying Cheng, Byoung Chul Cho, Timuçin Çil, Alexis B. Cortot, Pongwut Danchaivijitr, Till‐Oliver Emde, Dilek Erdem, Enriqueta Felip, F. Estevinho, Maria Lurdes Ferreira, Flavio Ferreira da Silva, Maria Campelo, Laurent Greillier, Alastair Greystoke, Ji‐Youn Han, Ping‐Chih Hsu, Jen‐Yu Hung, Mei Ji, Thomas John, Rohit Joshi, Young‐Chul Kim, Masashi Kondo, Ernesto Korbenfeld, Dariusz M. Kowalski, Se‐Hoon Lee, Natasha B. Leighl, Juan Li, Sheng-Hao Lin, Baogang Liu, Caigang Liu, John Seng-Hooi Low, Melina E. Marmarelis, Bartomeu Massutí, Anna R. Minchom, Sara Moore, Mor Moskovitz, Adnan Nagrial, Danny Nguyen, Silvia Novello, Y. Ohe, Mustafa Özgüroğlu, Özgür Özyılkan, Antonio Passaro, Nir Peled, Naiyarat Prasongsook, Angel Qin, Elisa F. Ramos ほか 22 名 - Journal of Clinical Oncology 2024 被引用: 114

  8. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 106

  9. Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 430

  10. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Solange Peters, Ross A. Soo, Ji‐Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki‐Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne‐Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki‐Voser, Susanne Roux, Barbara Ruepp, Magdalena Sánchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, M. Reist, Priska Rentsch, Linda Coate, Sinéad Cuffe, Sayed M.S. Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario García Campelo, Bartomeu Massutí, José López García, Manuel Dómine, Margarita Majem, José Miguel Sánchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross A. Soo, Chong Ming Yeo, Ji‐Youn Han, Byoung Chul Cho - Annals of Oncology 2021 被引用: 116

  11. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2015 被引用: 357

  12. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 被引用: 62

  13. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2024 被引用: 69

  14. Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 434

  15. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Meike Limburg, Mariano Provencio, Niki Karachaliou, Sabine Merkelbach‐Bruse, Martin Hellmich, Lucia Nogová, Reinhard Büttner, Rafael Rosell, Jürgen Wolf - Journal of Thoracic Oncology 2019 被引用: 131

  16. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 242

  17. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

    著者: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2022 被引用: 50

  18. Lung cancer symptoms at diagnosis: results of a nationwide registry study

    著者: , , , , , , , , , , , , , , , , , , , , , , , - ESMO Open 2020 被引用: 78

  19. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2020 被引用: 106

  20. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical and Translational Medicine 2021 被引用: 56

  21. Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , - Clinical Cancer Research 2014 被引用: 198

  22. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 67

  23. Machine Learning–Assisted Recurrence Prediction for Patients With Early-Stage Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , - JCO Clinical Cancer Informatics 2023 被引用: 27

  24. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2014 被引用: 133